SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-22-024906
Filing Date
2022-09-14
Accepted
2022-09-14 16:14:45
Documents
18
Period of Report
2022-09-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K pnt-20220913.htm   iXBRL 8-K 41823
2 EX-1.1 exhibit11-8xk.htm EX-1.1 317689
3 EX-5.1 exhibit51-8xk.htm EX-5.1 15677
4 EX-99.1 pricingannouncementex9918-k.htm EX-99.1 14892
8 image_0.jpg GRAPHIC 11382
9 point-logoxcolour.jpg GRAPHIC 124067
10 point-logoxcolour1.jpg GRAPHIC 17537
  Complete submission text file 0001628280-22-024906.txt   816517

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT pnt-20220913.xsd EX-101.SCH 2020
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT pnt-20220913_lab.xml EX-101.LAB 24927
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT pnt-20220913_pre.xml EX-101.PRE 13243
12 EXTRACTED XBRL INSTANCE DOCUMENT pnt-20220913_htm.xml XML 11403
Mailing Address 4850 WEST 78TH STREET INDIANAPOLIS IN 46268
Business Address 4850 WEST 78TH STREET INDIANAPOLIS IN 46268 (317) 543-9957
POINT Biopharma Global Inc. (Filer) CIK: 0001811764 (see all company filings)

IRS No.: 850800493 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39373 | Film No.: 221243142
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences